PET-CT and the detection of the asymptomatic recurrence or second primary lesions in the treated head and neck cancer patient

Laryngoscope

Volumn 123, Issue 9, 2013, Pages 2161-2164

  Dunsky, Katherine A ^a   Wehrmann, Daniel J ^d   Osman, Medhat M ^c   Thornberry, Brandon M ^b   Varvares, Mark A ^d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SAINT LOUIS UNIVERSITY   (United States)

Author keywords

PET CT; recurrent head and neck cancer

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADVANCED CANCER; ARTICLE; ASYMPTOMATIC DISEASE; CANCER DIAGNOSIS; CANCER MORTALITY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER TOMOGRAPHY SCANNER; FEMALE; FOLLOW UP; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LARYNX SQUAMOUS CELL CARCINOMA; LUNG LESION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MOUTH SQUAMOUS CELL CARCINOMA; NECK METASTASIS; PHARYNX CARCINOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TUMOR RECURRENCE;

PET/CT; RECURRENT HEAD AND NECK CANCER;

ADULT; AGED; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84883148173     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1002/lary.23941     Document Type: Article

References (13)

1. Branstetter BF 4th, Blodgett TM, Zimmer LA, et al. Head and neck malignancy: is PET/CT more accurate than PET or CT alone? Radiology 2005; 235: 580-586.
2. Schoder H, et al. Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology 2004; 231: 65-72.
3. Agarwal A, Hammond T H, Young G, Avon A, Ozer E, Schuller D,. Factors effecting long-term survival in patients with recurrent head and neck cancer may help define the role of post-treatment surveillance. Laryngoscope 2009; 119: 2135-2140.
4. Edge SB, Byrd, DR, Compton, CC, Fritz AG,. American Joint Committee on Cancer. AJCC Cancer Staging Manual, 7th ed. New York, NY: Springer; 2010.
5. Scharpf J, Karnell LH, Christensen AJ, Funk GF,. The role of pain in head and neck cancer recurrence and survivorship. Arch Otolaryngol Head Neck Surg 2009; 135: 789-794.
6. Smit M, Balm AJ, Hilgers FJ, Tan IB,. Pain as sign of recurrent disease in head and neck squamous cell carcinoma. Head Neck 2001; 23: 372-375.
7. Lowe VJ, Boyd JH, Dunphy FR, et al. Surveillance for recurrent head and neck cancer using positron emission tomography. J Clin Oncol 2000; 18: 651-658.
8. Krabbe CA, Pruim J, Dijkstra PU, et al. 18F-FDG PET as a routine posttreatment surveillance tool in oral and oropharyngeal squamous cell carcinoma: a prospective study. J Nucl Med 2009; 50: 1940-1947.
9. Francis DO, Yueh B, Weymuller EA Jr, Merati AL,. Impact of surveillance on survival after laryngeal cancer in the medicare population. Laryngoscope 2009; 119: 2337-2344.
10. de Visscher AV, Manni JJ,. Routine long-term follow-up in patients treated with curative intent for squamous cell carcinoma of the larynx, pharynx, and oral cavity. Does it make sense? Arch Otolaryngol Head Neck Surg 1994; 120: 934-939.
11. Boysen M, Natvig K, Winther FO, Tausjo J,. Value of routine follow-up in patients treated for squamous cell carcinoma of the head and neck. J Otolaryngol 1985; 14: 211-214.
12. Lester SE, Wight RG,. 'When will I see you again?' Using local recurrence data to develop a regimen for routine surveillance in post-treatment head and neck cancer patients. Clin Otolaryngol 2009; 34: 546-551.
13. Sher DJ, Tishler RB, Annino D, Punglia RS,. Cost-effectiveness of CT and PET-CT for determining the need for adjuvant neck dissection in locally advanced head and neck cancer. Ann Oncol 2009; 21: 1072-1077. Epub 2009.